TICKERNERD
Menu
DNTHDNTHHealthcare · Biotechnology

DNTH Stock Forecast: Dianthus Therapeutics, Inc. Price Predictions for 2026-2027

Last close, 3 Aug 2026
$106
−0.84% on the day

The 15 Wall Street analysts covering Dianthus Therapeutics, Inc. hold a median 12-month price target of $125 — +17.9% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 53 of 100 as at 1 Aug 2026 — in the upper half.

Market cap
$5.8B
Ticker Nerd rank
53 / 100
Median analyst target
$125
Analysts covering
15
Total return, dividends reinvested
1W
+1.5%
1M
+12.4%
YTD
+157.3%
1Y
+414.9%
From 52W high
−5.9%
From 52W low
+465.1%
$19
$113
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

DNTH stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Dianthus Therapeutics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 1 Aug 2026
53 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Momentum
100
Volatility
85
Value
75
Quality
71
Revisions
48
Accruals
41
Growth
30
Issuance
28
Size
22

Momentum (100): The shares have been drifting up relative to others.

Issuance (28): The company has been issuing shares or taking on financing, diluting existing holders.

Size (22): Larger than most of the companies we track — more scrutinised, less often mispriced.

The rank is the raw material. Whether the rules would actually own Dianthus Therapeutics, Inc. — and when they’d sell — is the membership.

Wall Street

DNTH stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on DNTH, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0$50$100$150$200Oct 25Jan 26Apr 26Jul 26DNTHHigh $200Median $125Low $105

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

What Wall Street says15 analysts
15 Buy0 Hold0 Sell
Low $105Median $125High $200

The green dot is the last close — the median target sits +17.9% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
6 May 2026WedbushMaintainsOutperform$103 → $105
6 May 2026WedbushMaintainsOutperform—
9 Apr 2026Wolfe ResearchInitiatesOutperform—
19 Mar 2026Wells FargoInitiatesOverweight—
12 Mar 2026WedbushMaintainsOutperform—
10 Mar 2026BairdMaintainsOutperform—
10 Mar 2026Clear StreetMaintainsBuy—
10 Mar 2026Raymond JamesUpgradeStrong Buy—
10 Mar 2026WedbushMaintainsOutperform—
9 Mar 2026HC Wainwright & Co.MaintainsBuy—
9 Mar 2026OppenheimerMaintainsOutperform—
9 Mar 2026Truist SecuritiesMaintainsBuy—
4 Mar 2026GuggenheimMaintainsBuy—
11 Feb 2026WedbushMaintainsOutperform—
2 Feb 2026JefferiesMaintainsBuy—
8 Jan 2026Truist SecuritiesMaintainsBuy—
22 Dec 2025WedbushReiteratesOutperform—
10 Nov 2025HC Wainwright & Co.MaintainsBuy—
6 Nov 2025WedbushMaintainsOutperform—
14 Oct 2025Truist SecuritiesInitiatesBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Estimates

DNTH analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
5
Analysts cutting
1
Fundamentals

Dianthus Therapeutics, Inc. (DNTH) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
3.3×

Cheaper than 68% of US stocks

Price / sales
4374.9×

Cheaper than 1% of US stocks

Price / book
4.9×

Cheaper than 22% of US stocks

EV / EBITDA
−24.8×

Cheaper than 90% of US stocks

Growth & margins
Revenue growth (YoY)
−60.2%

Higher than 4% of US stocks

Earnings growth (YoY)
−60.2%

Higher than 8% of US stocks

Gross margin
—
Operating margin
−10050.3%

Higher than 2% of US stocks

Net margin
0.0%

Higher than 30% of US stocks

Returns & dividend
Return on equity
−22.7%

Higher than 30% of US stocks

Return on assets
−15.0%

Higher than 23% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Peers

DNTH vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
DNTHDianthus Therapeutics, Inc.$5.8B
53
ORKAOruka Therapeutics, Inc.$5.8B
48
XENEXenon Pharmaceuticals, Inc.$6.0B
43
LGNDLigand Pharmaceuticals, Inc.$5.7B
75
DFTXDefinium Therapeutics, Inc.$5.6B
38
PTCTPTC Therapeutics, Inc.$5.6B
70
ERASErasca, Inc.$6.2B
66
Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. DNTH appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

News

Latest DNTH news & analysis

Dianthus Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(C)(4)

GlobeNewsWire · 3 Aug 2026neutral

Dianthus Therapeutics announced that on August 3, 2026, it granted equity awards, described as inducement grants under NASDAQ Listing Rule 5635(C)(4), to six newly-hired, non-executive employees. The company is a clinical-stage biotechnology firm focused on treatments for severe autoimmune diseases.

Why it matters — A DNTH watcher would care because the inducement equity grants signal recent additions to the company's workforce, which is relevant to its operations as a clinical-stage biotech, though the announcement contains no business or financial updates.

FAQ

Frequently asked questions about DNTH stock

What is the DNTH stock price forecast for 2026-2027?

The 15 Wall Street analysts covering Dianthus Therapeutics, Inc. have a median 12-month price target of $125, with estimates ranging from $105 to $200. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is DNTH stock a buy right now?

Of the 15 analysts covering Dianthus Therapeutics, Inc., 15 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Dianthus Therapeutics, Inc. 53 out of 100 across roughly 4,600 US stocks as at 1 Aug 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank DNTH?

As at 1 Aug 2026, Dianthus Therapeutics, Inc. ranks 53 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Momentum (100 of 100).

Will DNTH stock go up?

No one can know that. What the data says: the median 12-month target from 15 analysts implies +17.9% from the last close, and Ticker Nerd's factor model ranks Dianthus Therapeutics, Inc. 53 out of 100 as at 1 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the DNTH stock forecast for 2030?

No analyst covering Dianthus Therapeutics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for DNTH are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $105 to $200 over the next 12 months.

How has DNTH stock performed over the past year?

Dianthus Therapeutics, Inc. returned +414.9% over the 12 months to 3 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Dianthus Therapeutics, Inc. do?

Dianthus Therapeutics Inc. is a clinical-stage biotechnology company focused on developing next-generation complement therapeutics for patients with severe autoimmune and inflammatory diseases.

What is the latest news on DNTH?

The most recent item we track (GlobeNewsWire, 3 Aug 2026): "Dianthus Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(C)(4)". Dianthus Therapeutics announced that on August 3, 2026, it granted equity awards, described as inducement grants under NASDAQ Listing Rule 5635(C)(4), to six newly-hired, non-executive employees. The company is a clinical-stage biotechnology firm focused on treatments for severe autoimmune diseases.

Company

About Dianthus Therapeutics, Inc.

Dianthus Therapeutics Inc. is a clinical-stage biotechnology company focused on developing next-generation complement therapeutics for patients with severe autoimmune and inflammatory diseases. It designs and delivers novel monoclonal antibodies and biologics with enhanced selectivity, potency, and dosing convenience compared to existing therapies, targeting validated immune pathways such as the classical complement pathway, plasmacytoid dendritic cells, and B cells. The company's lead candidate, DNTH103 (claseprubart), is a subcutaneous active C1s inhibitor in clinical trials for neuromuscular indications including generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, and multifocal motor neuropathy. DNTH212, a bifunctional fusion protein, addresses both innate and adaptive immune responses by reducing type 1 interferon production and suppressing B-cell function. Dianthus Therapeutics Inc. operates in the healthcare biotechnology sector, advancing investigational medicines aimed at transforming treatment options for immune-mediated conditions. Founded in 2019 and headquartered in New York, New York, with additional presence in Waltham, Massachusetts, the company is led by an experienced team of biotechnology and pharmaceutical executives.

CEO Mr. Marino Garcia M.B.A. · 78 employees · United States · https://dianthustx.com